Home / Stocks / UTHR

UNITED THERAPEUTICS (UTHR, Biotech) Stock Valuation & Fair Value

Mixed on our tests

UNITED THERAPEUTICS (UTHR, Biotech) trades at a current P/E of 23.3, about 2% below its historical normal valuation, with a forward growth estimate of 22.7% and a PEG of 1.03. Analysts' one-year estimates have been hit 36% of the time. Priced at its historical normal P/E of 23.8 on the same blended earnings, the 2026-11-06 close of $562.02 corresponds to about $574 a share. This is a valuation reference, not a price target.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

DATA AS OF 2026-11-07
Current P/E
23.3
Normal P/E
23.8
PEG
1.03
Fwd growth
22.7%
Div yield
0.0%
RSI (14)
48.8
Neutral
Technical context
  • Price $562.02 at the Nov 6 close, 1.7% below the 20-day average ($571.87) and 5.2% above the 50-day ($533.99).
  • RSI (14) at 48.8.
  • 52-week range $448.91 to $608.49: the price is 7.6% below the high and 25.2% above the low.

The Street vs SeerForecast

Wall Street's mean price target for UTHR is $670.93 across 14 analysts, 19.4% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from favorable on our tests (2026-07-31) to mixed on our tests (2026-11-02).

Current P/E and rating by weekCurrent P/E moved from 19.1 to 22.4 between 2026-07-31 and 2026-10-30, against a normal P/E of 23.8, with 4 rating changes over 14 recorded weeks.2026-07-31: P/E 19.1, Favorable on our tests, recalculated for the week of 2026-07-312026-07-31: P/E 18.8, Favorable on our tests, recorded live 2026-08-032026-08-07: P/E 18.8, Favorable on our tests, recalculated for the week of 2026-08-072026-08-07: P/E 20.0, Weak on forward returns, recorded live 2026-08-102026-08-14: P/E 20.0, Weak on forward returns, recalculated for the week of 2026-08-142026-08-14: P/E 18.6, Mixed on our tests, recorded live 2026-08-172026-08-21: P/E 18.6, Mixed on our tests, recalculated for the week of 2026-08-212026-08-21: P/E 19.1, Mixed on our tests, recorded live 2026-08-242026-08-27: P/E 19.1, Mixed on our tests, recalculated for the week of 2026-08-272026-08-28: P/E 19.1, Mixed on our tests, recalculated for the week of 2026-08-282026-08-28: P/E 19.1, Mixed on our tests, recalculated for the week of 2026-08-302026-08-28: P/E 19.2, Mixed on our tests, recorded live 2026-08-312026-09-04: P/E 19.2, Mixed on our tests, recalculated for the week of 2026-09-052026-09-04: P/E 18.2, Mixed on our tests, recorded live 2026-09-072026-09-11: P/E 18.2, Mixed on our tests, recalculated for the week of 2026-09-122026-09-11: P/E 18.6, Mixed on our tests, recorded live 2026-09-142026-09-18: P/E 18.6, Mixed on our tests, recalculated for the week of 2026-09-192026-09-18: P/E 18.5, Mixed on our tests, recorded live 2026-09-212026-09-25: P/E 17.7, Mixed on our tests, recalculated for the week of 2026-09-262026-09-25: P/E 17.7, Mixed on our tests, recorded live 2026-09-282026-10-02: P/E 20.2, Weak on forward returns, recalculated for the week of 2026-10-032026-10-02: P/E 20.2, Weak on forward returns, recorded live 2026-10-052026-10-09: P/E 20.5, Weak on forward returns, recalculated for the week of 2026-10-102026-10-09: P/E 20.5, Weak on forward returns, recorded live 2026-10-122026-10-16: P/E 19.8, Mixed on our tests, recalculated for the week of 2026-10-172026-10-16: P/E 19.8, Mixed on our tests, recorded live 2026-10-192026-10-23: P/E 21.9, Mixed on our tests, recalculated for the week of 2026-10-242026-10-23: P/E 21.9, Mixed on our tests, recorded live 2026-10-262026-10-30: P/E 22.4, Mixed on our tests, recalculated for the week of 2026-10-312026-10-30: P/E 22.4, Mixed on our tests, recorded live 2026-11-0218.020.022.0Jul 31Aug 23Sep 15Oct 7Oct 30Normal P/E 23.8
Favorable on our testsMixed on our testsWeak on forward returns

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 19.1-20%Favorable on our tests (recalculated)
2026-08-10P/E 20.0-16%Weak on forward returns
2026-08-17P/E 18.6-22%Mixed on our tests
2026-09-26P/E 17.7-25%Mixed on our tests (recalculated)
2026-10-03P/E 20.2-15%Weak on forward returns (recalculated)
2026-10-17P/E 19.8-17%Mixed on our tests (recalculated)
2026-10-31P/E 22.4-6%Mixed on our tests (recalculated)
2026-11-02P/E 22.4-6%Mixed on our tests ← now
Show all 30 readings
WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 19.1-20%Favorable on our tests (recalculated)
2026-08-03P/E 18.8-21%Favorable on our tests
2026-08-07P/E 18.8-21%Favorable on our tests (recalculated)
2026-08-10P/E 20.0-16%Weak on forward returns
2026-08-14P/E 20.0-16%Weak on forward returns (recalculated)
2026-08-17P/E 18.6-22%Mixed on our tests
2026-08-21P/E 18.6-22%Mixed on our tests (recalculated)
2026-08-24P/E 19.1-20%Mixed on our tests
2026-08-27P/E 19.1-20%Mixed on our tests (recalculated)
2026-08-28P/E 19.1-20%Mixed on our tests (recalculated)
2026-08-30P/E 19.1-20%Mixed on our tests (recalculated)
2026-08-31P/E 19.2-19%Mixed on our tests
2026-09-05P/E 19.2-19%Mixed on our tests (recalculated)
2026-09-07P/E 18.2-24%Mixed on our tests
2026-09-12P/E 18.2-24%Mixed on our tests (recalculated)
2026-09-14P/E 18.6-22%Mixed on our tests
2026-09-19P/E 18.6-22%Mixed on our tests (recalculated)
2026-09-21P/E 18.5-22%Mixed on our tests
2026-09-26P/E 17.7-25%Mixed on our tests (recalculated)
2026-09-28P/E 17.7-25%Mixed on our tests
2026-10-03P/E 20.2-15%Weak on forward returns (recalculated)
2026-10-05P/E 20.2-15%Weak on forward returns
2026-10-10P/E 20.5-14%Weak on forward returns (recalculated)
2026-10-12P/E 20.5-14%Weak on forward returns
2026-10-17P/E 19.8-17%Mixed on our tests (recalculated)
2026-10-19P/E 19.8-17%Mixed on our tests
2026-10-24P/E 21.9-8%Mixed on our tests (recalculated)
2026-10-26P/E 21.9-8%Mixed on our tests
2026-10-31P/E 22.4-6%Mixed on our tests (recalculated)
2026-11-02P/E 22.4-6%Mixed on our tests ← now

Frequently asked questions

Is UNITED THERAPEUTICS stock overvalued?

At a current P/E of 23.3 versus its historical normal P/E of 23.8, UNITED THERAPEUTICS trades about 2% below its typical valuation, with a PEG of 1.03 on 22.7% forward growth. tickerseer currently rates it mixed on our tests.

What is UNITED THERAPEUTICS's fair value and PEG?

UNITED THERAPEUTICS trades at a current P/E of 23.3 against a historical normal P/E of 23.8, a PEG of 1.03, and a forward growth estimate of 22.7%. Priced at its historical normal P/E of 23.8 on the same blended earnings, the 2026-11-06 close of $562.02 corresponds to about $574 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of UNITED THERAPEUTICS changed?

tickerseer's rating moved from favorable on our tests (2026-07-31) to mixed on our tests (2026-11-02).

What is the analyst price target for UNITED THERAPEUTICS?

The mean Wall Street price target for UNITED THERAPEUTICS is $670.93 across 14 analysts, 19.4% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotech. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track UTHR free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.